Deka has developed the next generation of cytokine therapy - Diakine™. Diakines™ are purposely engineered therapeutic proteins that are designed to deliver clinically validated cytokine combinations to diseased tissue.
Deka uses Precision Medicine to identify patients that will benefit from their Diakines™, because not everyone responds to a given cytokine in the same way. They have developed the appropriate assays and discovered the underlying genetic signatures that are responsible for the differential responses to Diakines™.
Deka is focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases such as Crohn’s, psoriasis, rheumatoid arthritis and sepsis.